Jvion’s AI primed to improve outcomes at every stage of care cycle

The American Hospital Association (AHA) recently released a Market Insight report on AI’s potential impact on care delivery. The prognosis is promising: the report concludes that — with the right infrastructure, vendor partnerships, and buy-in from clinicians and patients — AI can prevent disease, detect important changes in patients’ medical conditions, diagnose patients faster and more accurately, and personalize treatment. In line with the report’s findings, Jvion’s AI is primed to improve outcomes at every stage: prevention, detection, diagnosis, and treatment.

Prevention

By keeping patients healthy and out of the hospital, preventive medicine is one of the most effective ways to improve outcomes and reduce costs. According to the expert panel and the published research behind the AHA’s report, “AI technologies can help hospitals and health systems keep people in their communities healthy and detect disease at an earlier stage.” Jvion’s AI is designed to support preventive care by identifying patients at risk of illness and recommending personalized early interventions.

Jvion’s AI solution — the Jvion CORE — has enabled clinicians to pinpoint at-risk patients for pneumonia vaccination initiatives, as well as patients at risk of chronic disease who could benefit from routine wellness screenings and check-ins. By analyzing socioeconomic, behavioral, and environmental data in addition to clinical data, the Jvion CORE accounts for social determinants of health and their impact on healthcare outcomes. This data enables the Jvion CORE to recommend interventions tailored to each patient’s unique circumstances, helping to mitigate healthcare disparities arising from social factors.

Detection

AI can process exponentially more data than a human can, giving it the power to detect patterns that would otherwise go unnoticed. The report concludes that AI’s predictive power will help clinicians detect medical events early and intervene upstream, before symptoms escalate. By identifying the clinical, behavioral, social, and environmental factors contributing to each patient’s risk, AI will enable clinicians to monitor vulnerable patients more closely and detect changes in their health more quickly.

The report specifically highlights AI’s ability to help clinicians reduce readmissions and adverse events in the hospital. Jvion has a proven track record of reducing both. With Jvion, providers have been able to more precisely target discharged patients with out-patient visits, successfully reducing readmissions by at least 10%. Jvion’s AI is also a valuable tool for preventing in-patient harm, including hospital-acquired infections, falls, pressure injuries, and sepsis. Armed with the knowledge of who is at risk, clinicians can more closely monitor the most vulnerable patients and apply personalized interventions to prevent harm.

Diagnosis

For many diseases, early diagnosis is one of the most critical determinants of patient outcomes. There is perhaps no greater example than sepsis, where mortality increases by up to 8% with each hour of delayed diagnosis. Unfortunately, recognizing the often ambiguous symptoms as sepsis can be a challenge for even the most experienced doctors. Jvion’s power to identify patients at risk of sepsis before any signs are present can help clinicians focus their limited resources to recognize and diagnose sepsis faster and start treatment sooner. Providers like Southeast Health have already demonstrated the value of Jvion for fighting sepsis, having successfully reduced sepsis by an average of 25.5% and avoiding $442,000 – $741,000 in costs each month.

Treatment

One of the most promising applications of AI outlined in the report is the personalization of treatment. Evidence-based protocols and established clinical pathways may work for most patients, but every patient is different, and a one-size-fits-all approach cannot effectively treat everybody. Worse, treatment plans that don’t factor in patients’ unique needs or risk of noncompliance can ultimately harm the patient. AI can help clinicians parse through the ever-expanding trove of medical knowledge to find the best treatment for each patient’s medical history, genetics, environment and social determinants of health. To that end, Jvion is the first and only clinical AI tool that can recommend clinically-validated, personalized interventions to reduce risk, engage patients, and prevent harm.

Conclusion

The AHA report comes as 62% of healthcare leaders have adopted a clinical AI strategy, an 88% increase in the last year. Indeed, AI is already having significant impacts on care delivery, from prevention to treatment. The potential of AI to personalize treatment, prevent harm, and improve outcomes is already here —  with Jvion, providers report average reductions of 30% in preventable harm incidents, and annual cost savings of $6.3M.

As the technology advances, the continued success of clinical AI will depend on buy-in from both patients and physicians. AI vendors have a responsibility to ensure providers can trust the AI to improve outcomes for their patients while protecting their privacy. Perhaps the most important point to understand is that AI will never replace clinicians. Rather, AI helps clinicians do what they do best: think critically and make the right decisions for their patients.